{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:23:33Z","timestamp":1785763413872,"version":"3.56.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900248"],"award-info":[{"award-number":["81900248"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10557-024-07636-3","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T02:02:01Z","timestamp":1729908121000},"page":"1125-1134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ticagrelor versus Clopidogrel in Patients with left main Coronary Artery Stenting"],"prefix":"10.1007","volume":"39","author":[{"given":"Yufeng","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-6944","authenticated-orcid":false,"given":"Yaguo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"key":"7636_CR1","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1056\/NEJMoa1610227","volume":"375","author":"GW Stone","year":"2016","unstructured":"Stone GW, Sabik JF, Serruys PW, Simonton CA, Genereux P, Puskas J, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med. 2016;375:2223\u201335.","journal-title":"N Engl J Med"},{"key":"7636_CR2","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1093\/eurheartj\/ehaa135","volume":"41","author":"Y Ahmad","year":"2020","unstructured":"Ahmad Y, Howard JP, Arnold AD, Cook CM, Prasad M, Ali ZA, et al. Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020;41:3228\u201335.","journal-title":"Eur Heart J"},{"key":"7636_CR3","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation. 2016;134:e123\u2013155.","journal-title":"Circulation"},{"key":"7636_CR4","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation. 2009;120:2577\u201385.","journal-title":"Circulation"},{"key":"7636_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","volume":"68","author":"G Giustino","year":"2016","unstructured":"Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68:1851\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"7636_CR6","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/eurheartj\/ehy238","volume":"40","author":"J Fajadet","year":"2019","unstructured":"Fajadet J, Capodanno D, Stone GW. Management of left main disease: an update. Eur Heart J. 2019;40:1454\u201366.","journal-title":"Eur Heart J"},{"key":"7636_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","volume":"375","author":"CP Cannon","year":"2010","unstructured":"Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375:283\u201393.","journal-title":"Lancet"},{"key":"7636_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"FJ Neumann","year":"2019","unstructured":"Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC\/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019;40:87\u2013165.","journal-title":"Eur Heart J"},{"key":"7636_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-thoracic surgery (EACTS). Eur Heart J. 2018;39:213\u201360.","journal-title":"Eur Heart J"},{"key":"7636_CR10","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.1093\/eurheartj\/ehad318","volume":"44","author":"HY Wang","year":"2023","unstructured":"Wang HY, Zhang R, Dou K, Huang Y, Xie L, Qiao Z, et al. Left main bifurcation stenting: impact of residual ischaemia on cardiovascular mortality. Eur Heart J. 2023;44:4324\u201336.","journal-title":"Eur Heart J"},{"key":"7636_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ahj.2021.02.014","volume":"236","author":"Z Ge","year":"2021","unstructured":"Ge Z, Gao XF, Kan J, Kong XQ, Zuo GF, Ye F, et al. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial. Am Heart J. 2021;236:49\u201358.","journal-title":"Am Heart J"},{"key":"7636_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/ehjcvp\/pvz048","volume":"6","author":"O De Filippo","year":"2020","unstructured":"De Filippo O, D\u2019Ascenzo F, Raposeiras-Roubin S, Abu-Assi E, Peyracchia M, Bocchino PP, et al. P2Y12 inhibitors in acute coronary syndrome patients with renal dysfunction: an analysis from the RENAMI and BleeMACS projects. Eur Heart J Cardiovasc Pharmacother. 2020;6:31\u201342.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"7636_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"7636_CR14","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1093\/eurheartj\/ehw284","volume":"37","author":"A Sahl\u00e9n","year":"2016","unstructured":"Sahl\u00e9n A, Varenhorst C, Lagerqvist B, Renlund H, Omerovic E, Erlinge D, et al. Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. Eur Heart J. 2016;37:3335\u201342.","journal-title":"Eur Heart J"},{"key":"7636_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.120.046786","volume":"142","author":"EP Navarese","year":"2020","unstructured":"Navarese EP, Khan SU, Kolodziejczak M, Kubica J, Buccheri S, Cannon CP, et al. Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation. 2020;142:150\u201360.","journal-title":"Circulation"},{"key":"7636_CR16","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jamainternmed.2019.6447","volume":"180","author":"RD Turgeon","year":"2020","unstructured":"Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT, et al. Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA Intern Med. 2020;180:420\u20138.","journal-title":"JAMA Intern Med"},{"key":"7636_CR17","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2020.16167","volume":"324","author":"SC You","year":"2020","unstructured":"You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, et al. Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA. 2020;324:1640\u201350.","journal-title":"JAMA"},{"key":"7636_CR18","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","volume":"395","author":"M Gimbel","year":"2020","unstructured":"Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, et al. Clopidogrel versus Ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395:1374\u201381.","journal-title":"Lancet"},{"key":"7636_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrcardio.2014.104","volume":"11","author":"GN Levine","year":"2014","unstructured":"Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, et al. Expert consensus document: world heart federation expert consensus statement on antiplatelet therapy in east Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11:597\u2013606.","journal-title":"Nat Rev Cardiol"},{"key":"7636_CR20","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1253\/circj.CJ-15-0112","volume":"79","author":"S Goto","year":"2015","unstructured":"Goto S, Huang CH, Park SJ, Emanuelsson H, Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. Circ J. 2015;79:2452\u201360.","journal-title":"Circ J"},{"key":"7636_CR21","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1161\/CIRCULATIONAHA.119.041766","volume":"140","author":"DW Park","year":"2019","unstructured":"Park DW, Kwon O, Jang JS, Yun SC, Park H, Kang DY, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation. 2019;140:1865\u201377.","journal-title":"Circulation"},{"key":"7636_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.mayocp.2023.02.004","volume":"98","author":"M Qiu","year":"2023","unstructured":"Qiu M, Na K, Qi Z, Zhou H, Li P, Xu K, et al. Contemporary use of ticagrelor vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GRACE risk score stratification-based analysis in a large-scale, real-world study from China. Mayo Clin Proc. 2023;98:1021\u201332.","journal-title":"Mayo Clin Proc."},{"key":"7636_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/FJC.0000000000000390","volume":"68","author":"X Tang","year":"2016","unstructured":"Tang X, Li R, Jing Q, Wang Q, Liu P, Zhang P, et al. Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Cardiovasc Pharmacol. 2016;68:115\u201320.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7636_CR24","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.jacc.2017.09.011","volume":"70","author":"RW Yeh","year":"2017","unstructured":"Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, et al. Lesion complexity and outcomes of extended dual antiplatelet therapy after percutaneous coronary intervention. J Am Coll Cardiol. 2017;70:2213\u201323.","journal-title":"J Am Coll Cardiol"},{"key":"7636_CR25","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1016\/j.jcin.2021.08.056","volume":"14","author":"M Chiarito","year":"2021","unstructured":"Chiarito M, Kini A, Roumeliotis A, Cao D, Power D, Sartori S, et al. Prevalence and impact of high bleeding risk in patients undergoing left main artery disease PCI. JACC Cardiovasc Interv. 2021;14:2447\u201357.","journal-title":"JACC Cardiovasc Interv"},{"key":"7636_CR26","first-page":"436","volume":"98","author":"N Yager","year":"2021","unstructured":"Yager N, Schulman-Marcus J, Torosoff M. Coronary anatomy and comorbidities impact on elective PCI outcomes in left main and multivessel coronary artery disease. Catheter Cardiovasc Interv. 2021;98:436\u201344.","journal-title":"Catheter Cardiovasc Interv"},{"key":"7636_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/09537104.2020.1754381","volume":"32","author":"X Wu","year":"2021","unstructured":"Wu X, You W, Wu Z, Wu Q, Jiang J, Yan H, et al. Ticagrelor versus clopidogrel for prevention of subclinical stent thrombosis detected by optical coherence tomography in patients with drug-eluting stent implantation-a multicenter and randomized study. Platelets. 2021;32:404\u201312.","journal-title":"Platelets"},{"key":"7636_CR28","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","volume":"403","author":"Z Ge","year":"2024","unstructured":"Ge Z, Kan J, Gao X, Raza A, Zhang JJ, Mohydin BS, et al. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024;403:1866\u201378.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"7636_CR29","first-page":"1395","volume":"99","author":"Y Li","year":"2022","unstructured":"Li Y, Li J, Qiu M, Ma S, Na K, Li X, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention. Catheter Cardiovasc Interv. 2022;99(Suppl 1):1395\u2013402.","journal-title":"Catheter Cardiovasc Interv"},{"key":"7636_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ahj.2014.04.001","volume":"168","author":"A Kotsia","year":"2014","unstructured":"Kotsia A, Brilakis ES, Held C, Cannon C, Steg GP, Meier B, et al. Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: insights from the PLATelet inhibition and patient outcomes (PLATO) trial. Am Heart J. 2014;168:68\u201375.","journal-title":"Am Heart J"},{"key":"7636_CR31","first-page":"319","volume":"34","author":"J Chandrasekhar","year":"2018","unstructured":"Chandrasekhar J, Baber U, Sartori S, Aquino M, Kini AS, Rao S, et al. Associations between complex PCI and prasugrel or clopidogrel use in patients with acute coronary syndrome who undergo PCI: from the PROMETHEUS study. Can J Cardiol. 2018;34:319\u201329.","journal-title":"Can J Cardiol"},{"key":"7636_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1253\/circj.CJ-20-0362","volume":"85","author":"J Choi","year":"2020","unstructured":"Choi J, Kim IS, Cho S, Kim JS, Hong SJ, Shin DH, et al. Optimal duration for dual antiplatelet therapy after left main coronary artery stenting. Circ J. 2020;85:59\u201368.","journal-title":"Circ J"},{"key":"7636_CR33","doi-asserted-by":"publisher","first-page":"e011536","DOI":"10.1161\/CIRCINTERVENTIONS.121.011536","volume":"15","author":"HY Wang","year":"2022","unstructured":"Wang HY, Dou KF, Guan C, Xie L, Huang Y, Zhang R, et al. New insights into long- versus short-term dual antiplatelet therapy duration in patients after stenting for left main coronary artery disease: findings from a prospective observational study. Circ Cardiovasc Interv. 2022;15:e011536.","journal-title":"Circ Cardiovasc Interv"},{"key":"7636_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.887748","volume":"9","author":"M Almendro-Delia","year":"2022","unstructured":"Almendro-Delia M, Blanco-Ponce E, Carmona-Carmona J, Arboleda Sanchez JA, Rodriguez Yanez JC, Soto Blanco JM, et al. Comparative safety and effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndrome: an on-treatment analysis from a multicenter registry. Front Cardiovasc Med. 2022;9: 887748.","journal-title":"Front Cardiovasc Med"},{"key":"7636_CR35","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2147\/CIA.S355210","volume":"17","author":"S Meng","year":"2022","unstructured":"Meng S, Guo L, Ye Z, Wang J, Ding H, Wu S, et al. Comparison of clinical outcomes between Ticagrelor and Clopidogrel in Elderly patients undergoing percutaneous coronary intervention: a Cohort Study. Clin Interv Aging. 2022;17:331\u201341.","journal-title":"Clin Interv Aging"},{"key":"7636_CR36","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(20)32236-4","volume":"396","author":"J Silvain","year":"2020","unstructured":"Silvain J, Lattuca B, Beygui F, Range G, Motovska Z, Dillinger JG, et al. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet. 2020;396:1737\u201344.","journal-title":"Lancet"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07636-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07636-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07636-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T17:03:47Z","timestamp":1762880627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07636-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7636"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07636-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"21 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors consent to the publication of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Nanjing First Hospital and was in line with the principles of the Declaration of Helsinki, with a waiver on the requirement for written informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}